Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Industrial Management & Data Systems ; : 37, 2022.
Article in English | Web of Science | ID: covidwho-1927496

ABSTRACT

Purpose Considering both online and offline service scenarios, this study aims to explore the factors affecting doctors' intention to offer consulting services in eHealth and compare the factors between the free- and paid-service doctors. The theory of reasoned action and social exchange theory are integrated to develop the research model that conceptualizes the role of extrinsic motivations, intrinsic motivations, costs, and attitudes in doctors' behavioral intentions. Design/methodology/approach Partial least square structural equation modeling (PLS-SEM) was leveraged to analyze 326 valid sample data. To provide robust results, three non-parametric multigroup analysis (MGA) methods, including the PLS-MGA, confidence set, and permutation test approaches, were applied to detect the potential heterogeneity between the free- and paid-service doctors. Findings The results with overall samples reveal that anticipated rewards, anticipated associations, anticipated contribution, and perceived fee are all positively related to attitude, which in turn positively influences behavioral intention, and that perceived fee positively moderates the relationship between attitude and behavioral intention. Attitude's full mediation is also confirmed. However, results vary between the two groups of doctors. The three MGA approaches return relatively convergent results, indicating that the effects of anticipated associations and perceived fee on attitude are significantly larger for the paid-service doctors, while that of anticipated rewards is found to be significantly larger for the free-service doctors. Originality/value eHealth, as a potential contactless alternative to face-to-face diagnoses, has recently attracted widespread attention, especially during the continued spread of COVID-19. Most existing studies have neglected the underlying heterogeneity between free- and paid-service doctors regarding their motivations to engage in online healthcare activities. This study advances the understanding of doctors' participation in eHealth by emphasizing their motivations derived from both online and offline service scenarios and comparing the differences between free- and paid-service doctors. Besides, horizontally comparing the results by applying diverse MGA approaches enriches empirical evidence for the selection of MGA approaches in PLS-SEM.

2.
2022 IEEE International Memory Workshop, IMW 2022 ; 2022.
Article in English | Scopus | ID: covidwho-1901470

ABSTRACT

Hyperdimensional computing (HDC) is a promising paradigm for large-scale genome sequencing. In this work, we explore the feasibility of the in-memory HDC on 3D NAND Flash for genome sequencing. We investigate the HDC engine with geographical region classification of SARS-CoV-2 genome sequences. The simulation results indicate the robustness of the classification accuracy despite the 3D NAND Flash non-idealities. The system performance is evaluated and it achieves 1.21× improvement on energy efficiency compared to PCM-based HDC engine. The area efficiency is also improved by 3.79×. © 2022 IEEE.

3.
PubMed; 2020.
Preprint in English | PubMed | ID: ppcovidwho-333508

ABSTRACT

BACKGROUND: Serological tests are crucial tools for assessments of SARS-CoV-2 exposure, infection and potential immunity. Their appropriate use and interpretation require accurate assay performance data. METHOD: We conducted an evaluation of 10 lateral flow assays (LFAs) and two ELISAs to detect anti-SARS-CoV-2 antibodies. The specimen set comprised 128 plasma or serum samples from 79 symptomatic SARS-CoV-2 RT-PCR-positive individuals;108 pre-COVID-19 negative controls;and 52 recent samples from individuals who underwent respiratory viral testing but were not diagnosed with Coronavirus Disease 2019 (COVID-19). Samples were blinded and LFA results were interpreted by two independent readers, using a standardized intensity scoring system. RESULTS: Among specimens from SARS-CoV-2 RT-PCR-positive individuals, the percent seropositive increased with time interval, peaking at 81.8-100.0% in samples taken >20 days after symptom onset. Test specificity ranged from 84.3-100.0% in pre-COVID-19 specimens. Specificity was higher when weak LFA bands were considered negative, but this decreased sensitivity. IgM detection was more variable than IgG, and detection was highest when IgM and IgG results were combined. Agreement between ELISAs and LFAs ranged from 75.7-94.8%. No consistent cross-reactivity was observed. CONCLUSION: Our evaluation showed heterogeneous assay performance. Reader training is key to reliable LFA performance, and can be tailored for survey goals. Informed use of serology will require evaluations covering the full spectrum of SARS-CoV-2 infections, from asymptomatic and mild infection to severe disease, and later convalescence. Well-designed studies to elucidate the mechanisms and serological correlates of protective immunity will be crucial to guide rational clinical and public health policies.

4.
South African Medical Journal ; 111(6):535-537, 2021.
Article in English | EMBASE | ID: covidwho-1264653

ABSTRACT

There have recently been safety concerns regarding an increased risk of vaccine-induced immune thrombotic thrombocytopenia (VITT) following administration of SARS-CoV-2 adenoviral vector vaccines. The Southern African Society of Thrombosis and Haemostasis reviewed the emerging literature on this idiosyncratic complication. A draft document was produced and revised by consensus agreement by a panel of professionals from various specialties. The recommendations were adjudicated by independent international experts to avoid local bias. We present concise, practical guidelines for the clinical management of VITT.

5.
Cancer Research ; 81(4 SUPPL), 2021.
Article in English | EMBASE | ID: covidwho-1186386

ABSTRACT

Background: Triple-negativebreast cancer (TNBC) has the highest rate of distant metastasis and poorestoverallsurvival among all breast cancer subtypes. Adagloxad simolenin (AS;OBI-822)is a therapeutic vaccine comprisingthe synthetically manufactured tumor-associatedantigen Globo H linked to the carrier protein keyhole limpethemocyanin (KLH).The KLH provides antigenic immune recognition and T-cell responses. AS isco-administered witha saponin-based adjuvant OBI-821 to induce a humoralresponse. A phase 2 trial showed that AS/OBI-821exhibiteda trend for superior progression-free survival vs placebo in patientswhose breast cancers had higher GloboHexpression. Administrationof AS/OBI-821 resulted in IgM and IgG anti-Globo H humoral response and atrendtowards improved PFS in patients with metastatic breast cancer overexpressingGlobo H. We describe therationale and design of GLORIA, an ongoing Phase III,randomized, open-label study to evaluate efficacy, safety, and quality of life(QoL) of AS plus standard of care (SOC) versus SOC alone in patients with high-risk, early-stage TNBC. The primary endpoint is invasive progression-freesurvival;secondary endpoints include overall survival, QoL, breastcancer-freeinterval, distant disease-free survival, safety, and tolerability. Trial Design: A phase 3 trial was initiated inDecember 2018 and had been slowly enrolling until being put on holddue to theCovid-19 pandemic. While the study wason hold the design waschanged from a placebo-control to astandard-of-care control trial based onfeedback from investigators and leading breast cancer advisers, that thenumberof placebo injections was a serious burden on patients. Furthermore, it wasapparent that blinding wasquestionable given the expected and frequent localskin inflammation and low-grade fevers that accompany theAS/OBI-821 vaccineadministration and the absence of these obvious clinical signs and symptoms with the normalsaline placebo control.The main changes to the protocol are as follows:Methods: Eligibility includes patients with TNBC (estrogen receptor/progesterone receptor <5%,and HER2-negative) with nonmetastatic disease and 1) either residual invasive disease of ≥1 cm in breast or ≥1 positiveaxillary node following neoadjuvantchemotherapy;Pathological Stage IIB or III disease treated with adequateadjuvant chemotherapy alone;received ≥4 cycles of standard taxane- and/oranthracycline-basedchemotherapy;randomized within 12 weeks of surgery, adjuvant multi-agent chemotherapy,or radiation therapy.Inaddition, tumors must express Globo H (H-score of ≥15 by central laboratory analysis using a validatedimmunohistochemical assay). Subjects in the AS/OBI-821 group will receive 30 μg of AS in combination with 100 μgofOBI-821.This revised study will start re-enrolling patients as soon as Covid-19 restrictions are lifted with the firstcountry being South Korea with an anticipated start date in Q4/2020.

SELECTION OF CITATIONS
SEARCH DETAIL